Nobori® Stent

Highlights

NOBORI 2

Largest real-life registry of Nobori® stent.
Enrolled 3068 consecutive patients with coronary artery disease eligible for treatment with Drug-Eluting Stent.

The 3 year clinical results of NOBORI 2 study show consistently low occurrence of clinical events throughout the trial.

Find out more about the NOBORI 2 three year results

Nobori® Highlights

NOBORI 2 large study published

Two-year data confirmed the excellent and sustained performance of the Nobori® drug eluting stent (DES) when used in high risk unselected patients.

Tuesday May 15th session

Treatment of left main and multivessel disease

Wednesday May 16th sessions

• Left main and bifurcation stenting

• STEMI patients with primary PCI:
the value of optical imaging-guidance

Thursday May 17th sessions

• High-risk ACS - NSTEMI

• Fast, effective, safe:
making the right choices in STEMI

Nobori® Newsroom

March 1, 2012

NOBORI 2 study confirms efficacy and long-term safety of the Nobori® DES in daily practice

The recently published two-year data from the large NOBORI 2 study confirmed the excellent and sustained performance of the Nobori® drug eluting stent (DES) when used in high risk unselected patients.

February 9, 2012

The power of clinical evidence on Nobori® stent was presented at JIM 2012 by Dr. G.B. Danzi (Milan, Italy)

December 19, 2011

Nobori Drug Eluting Stent
Now available in a wider range of sizes!
Terumo receives CE Mark for 2.25 mm and 4.0 mm DES

Now more patients can benefit from this stent known for both its safety and efficacy. Read more about the positive clinical results of Nobori®

All news